NCT00052052

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: InterMune · Industry
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.

Conditions

• Lung Disease
• Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	interferon-gamma 1b	200 mcg, SQ, 3x per week

Timeline

• Start date: 2002-09-01
• Completion: 2004-09-01
• First posted: 2003-01-23
• Last updated: 2007-11-06

Locations

1 site across 1 country: United States